PCA
IMNM icon

Private Capital Advisors’s Immunome IMNM Stock Holding History

Private Capital Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$745K Buy
34,082
+10,542
+45% +$235K 0.09% 42
2025
Q4 		$506K Sell
23,540
-94,506
-80% -$1.66M 0.05% 53
2025
Q3 		$1.38M Sell
118,046
-71,798
-38% -$714K 0.15% 40
2025
Q2 		$1.77M Buy
189,844
+151,343
+393% +$1.24M 0.22% 36
2025
Q1 		$259K Buy
+38,501
New +$369K 0.03% 65

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Private Capital Advisors's IMNM Position: Q1 2026 in Review

Private Capital Advisors increased its Immunome (IMNM) stake by 45% in Q1 2026, buying an estimated $235K and bringing the position to 34,082 shares worth $745K. The position accounts for 0.09% of the portfolio, ranked #42.

Private Capital Advisors first reported a position in IMNM in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.77M in Q2 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Private Capital Advisors held 34,082 shares of Immunome worth $745K as of Q1 2026.
  • Private Capital Advisors bought 10,542 Immunome shares in Q1 2026, an estimated $235K.
  • Immunome made up 0.09% of Private Capital Advisors's portfolio in Q1 2026, its #42 holding.
  • Private Capital Advisors first reported a position in Immunome in Q1 2025 and has held it in 5 quarters since.
  • Private Capital Advisors's Immunome position peaked at $1.77M in Q2 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Private Capital Advisors's 13F filing for Q1 2026, filed 12 May 2026.